ABBVIE

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 2013-01-01

Employees: -

Market Cap: $346B

Website: http://www.abbvie.com

Clinical Trials

Effectiveness of Paritaprevir/Ritonavir - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Belgium

Completed

Conditions: Chronic Hepatitis C, Genotype 1 or 4

Interventions: Drug: Ombitasvir/paritaprevir/ritonavir
Drug: Dasabuvir
Drug: Ribavirin

First Posted Date: 2015-10-20

Last Posted Date: 2019-05-06

Lead Sponsor: AbbVie

Target Recruit Count: 314

Registration Number: NCT02581163

The Durability of Response and Persistence of Resistance to AbbVie's 2 Direct-acting Antiviral Agent (2D) Therapy in Japanese Subjects

Completed

Conditions: Hepatitis C Virus

First Posted Date: 2015-10-20

Last Posted Date: 2021-12-08

Lead Sponsor: AbbVie

Target Recruit Count: 344

Registration Number: NCT02581020

Locations: 🇯🇵
Kurume University Hospital /ID# 152123, Kurume-shi, Fukuoka, Japan
🇯🇵
Kawasaki Municipal Tama Hospit /ID# 153546, Kawasaki, Japan
🇯🇵
Hiroshima University Hospital /ID# 152232, Hiroshima-shi, Hiroshima, Japan

and more 50 locations

Post-Marketing Surveillance of Humira in Korean Pediatric Crohn's Disease (CD) Patients Under the "New-Drug Re-examination"

Completed

Conditions: Pediatric Crohn's Disease

First Posted Date: 2015-10-16

Last Posted Date: 2018-12-19

Lead Sponsor: AbbVie

Target Recruit Count: 143

Registration Number: NCT02578238

Safety, Tolerability and the Effects on Cerebrospinal Fluid Spectrin Breakdown Product-145 Levels of ABT-957 in Subjects With Mild Alzheimer's Disease and Mild Cognitive Impairment

Phase 1

Terminated

Conditions: Alzheimer's Disease
Mild Cognitive Impairment

Interventions: Drug: ABT-957
Other: Placebo

First Posted Date: 2015-10-12

Last Posted Date: 2021-07-06

Lead Sponsor: AbbVie

Target Recruit Count: 8

Registration Number: NCT02573740

Locations: 🇺🇸
Site Reference ID/Investigator# 149481, Dallas, Texas, United States
🇺🇸
Site Reference ID/Investigator# 143180, Cypress, California, United States
🇺🇸
Site Reference ID/Investigator# 143178, Orlando, Florida, United States

and more 6 locations

A Study of ABT-414 in Participants With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification

Phase 3

Completed

Conditions: Glioblastoma
Gliosarcoma

Interventions: Drug: Temozolomide
Radiation: Radiation
Drug: Depatuxizumab mafodotin
Drug: Placebo for ABT-414

First Posted Date: 2015-10-09

Last Posted Date: 2023-05-11

Lead Sponsor: AbbVie

Target Recruit Count: 691

Registration Number: NCT02573324

Locations: 🇺🇸
Piedmont Hospital /ID# 145892, Atlanta, Georgia, United States
🇺🇸
Emory Midtown Infectious Disease Clinic /ID# 144015, Atlanta, Georgia, United States
🇺🇸
University of Pennsylvania Medical Center - Shadyside /ID# 144159, Pittsburgh, Pennsylvania, United States

and more 209 locations

ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors

Phase 1

Completed

Conditions: Advanced Solid Tumors
Undifferentiated Pleomorphic Sarcoma
Squamous Cell Carcinoma of the Head and Neck
Carcinoma of the Breast

Interventions: Drug: ABBV-085

First Posted Date: 2015-10-01

Last Posted Date: 2019-04-05

Lead Sponsor: AbbVie

Target Recruit Count: 85

Registration Number: NCT02565758

Locations: 🇺🇸
Carolina BioOncology Institute /ID# 148583, Huntersville, North Carolina, United States
🇺🇸
NYU Langone Medical Center /ID# 150786, New York, New York, United States
🇺🇸
Greenville Hospital System /ID# 148652, Greenville, South Carolina, United States

and more 17 locations

RST-001 Phase I/II Trial for Advanced Retinitis Pigmentosa

Phase 1

Completed

Conditions: Advanced Retinitis Pigmentosa

Interventions: Drug: RST-001

First Posted Date: 2015-09-22

Last Posted Date: 2024-11-08

Lead Sponsor: AbbVie

Target Recruit Count: 14

Registration Number: NCT02556736

Locations: 🇺🇸
Retina Foundation of the Southwest, Dallas, Texas, United States
🇺🇸
Duke Eye Center, Durham, North Carolina, United States
🇺🇸
Cincinnati Eye Institute, Cincinnati, Ohio, United States

and more 1 locations

A Study to Examine the Effect of Levodopa-Carbidopa Intestinal Gel (LCIG) Therapy Relative to That of Optimized Medical Treatment (OMT) on Non-motor Symptoms (NMS) Associated With Advanced Parkinson's Disease (PD)

Phase 3

Completed

Conditions: Advanced Parkinson's Disease

Interventions: Drug: Optimized Medical Treatment
Device: Nasojejunal (NJ) tube
Drug: Levodopa-Carbidopa Intestinal Gel
Device: Percutaneous endoscopic gastrostomy with a jejunal (PEG-J) tube

First Posted Date: 2015-09-15

Last Posted Date: 2023-11-28

Lead Sponsor: AbbVie

Target Recruit Count: 89

Registration Number: NCT02549092

Locations: 🇨🇦
Toronto Western Hospital /ID# 136585, Toronto, Ontario, Canada
🇬🇷
Mediterraneo Hospital /ID# 208042, Glyfada, Greece
🇨🇦
University of Alberta /ID# 136586, Edmonton, Alberta, Canada

and more 35 locations

Pharmacokinetics and Safety of the Co-administration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Healthy Chinese Subjects

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: ABT-450/r/ABT-267
Drug: ABT-333

First Posted Date: 2015-08-28

Last Posted Date: 2015-10-19

Lead Sponsor: AbbVie

Target Recruit Count: 18

Registration Number: NCT02534870

Locations: 🇨🇳
Site Reference ID/Investigator# 137655, Shanghai, China

Study to Investigate Efficacy and Safety of Adalimumab in Japanese Subjects With Generalized Pustular Psoriasis (GPP)

Phase 3

Completed

Conditions: Generalized Pustular Psoriasis (GPP)
Adalimumab
Japanese

Interventions: Drug: Adalimumab

First Posted Date: 2015-08-26

Last Posted Date: 2019-01-14

Lead Sponsor: AbbVie

Target Recruit Count: 10

Registration Number: NCT02533375

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy